Myeloproliferative neoplasm screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

There are currently no guidelines for screening for myeloproliferative neoplasm. Monitoring of the complete blood count is done routinely.

Screening

There are currently no guidelines for screening for myeloproliferative neoplasm. Routine monitoring of complete blood count (CBC) once yearly is sufficient for screening for hematologic diseases in general.^[1]

References

↑ Rumi E, Cazzola M (2017). “Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms”. Blood. 129 (6): 680–692. doi:10.1182/blood-2016-10-695957. PMC 5335805. PMID 28028026.

Template:WH Template:WS

[pmid28028026-1] Rumi E, Cazzola M (2017). “Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms”. Blood. 129 (6): 680–692. doi:10.1182/blood-2016-10-695957. PMC 5335805. PMID 28028026.

[1]